PAI Partners has entered into exclusive negotiations to acquire the European specialty pharma company from Astorg.
On May 9, it was announced that Willkie client PAI Partners has entered into exclusive negotiations to acquire leading European specialty pharmaceutical company Ethypharm from private equity firm Astorg. PAI will acquire the company alongside Ethypharm’s management team.
PAI is a leading European private equity firm with offices in Paris, London, Luxembourg, Madrid, Milan, Munich and Stockholm. PAI manages over €8 billion of dedicated buyout funds. The equity for the Ethypharm transaction would be provided by PAI Europe VI, PAI’s latest €3.3 billion fund.
Leveraging its expertise in the formulation, development, registration and production of drugs with complex dosage forms, especially opioids, Ethypharm focuses on the treatment of pain and addictions. With a presence in France, Germany, the UK, Canada, the United States and China, Ethypharm generates over €200 million of sales.
The Willkie deal team was led by partner Eduardo Fernandez and included partners François Feuillat, Jeffrey Hochman and David Tayar; special European counsel Karine Lenczner; and associates David Lambert, Thomas Saint-Loubert-Bie, Ilan Aboukrat, Grégoire Dumazy, Camille Rezette, Gerry Kelly, David Austin and David Kupka.